Concord Drugs Share Price History and Returns 2015 to 2024
Concord Drugs Limited | |||
 | Price: ₹37.10 | ||
| 52 Week Low: ₹30.59 52 Week High: ₹61.50 | |||
| Market Capital: 31.34 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Concord Drugs Stock Highlights
- 1.1: 52-Week High Low
- 1.2: All Time High
- 2: Concord Drugs Recent Performance
- 3: Concord Drugs Stock Price Chart From 2015 to 2024
- 4: Concord Drugs Stock Price History Table From 2015 to 2024
- 5: Analyzing the Impact of Investing in Concord Drugs
- 5.1: Concord Drugs Stock Returns In Last 5 Years
- 6: Concord Drugs Returns vs Bank FD Returns
Concord Drugs Stock Highlights
As of 26 Dec 2024, Concord Drugs Stock price is ₹37.10 which is ₹24.40 below 52-week high of ₹61.50 and ₹6.51 above 52-week low of ₹30.59
52-Week High Low
- Concord Drugs 52-Week High is ₹61.50 occurred on 29 Dec 2023
- Concord Drugs 52-Week Low is ₹30.59 occurred on 13 Aug 2024
All Time High
- The all-time high or the highest price that Concord Drugs stocks have ever touched was ₹91.25 and this occurred on 27 Dec 2024.
- The highest closing price at which Concord Drugs stocks have ever closed was ₹78.95 recorded on 27 Dec 2024.
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Concord Drugs Recent Performance
Over the past 15 trading days, the value of Concord Drugs's stock has decreased by ₹0.91 (-2.39%). On 05 Dec 2024, its one share was worth ₹38.01 and by 26 Dec 2024, the value dropped to ₹37.1. During this period it created a highest high of ₹39.99 and lowest low of ₹35.52.
Click on legend items to show/hide respective price lines
Concord Drugs Stock Price Chart From 2015 to 2024
Click on legend items to show/hide respective price lines
Concord Drugs Stock Price History Table From 2015 to 2024
| Year | Concord Drugs | YOY Chg% | ↑High - ↓Low |
|---|---|---|---|
| 2024 | ₹37.10 | -37.9% | ↑ ₹59.00 ↓ ₹30.59 |
| 2023 | ₹59.72 | 83.4% | ↑ ₹61.50 ↓ ₹24.80 |
| 2022 | ₹32.55 | 1.2% | ↑ ₹41.65 ↓ ₹19.50 |
| 2021 | ₹32.15 | 40.3% | ↑ ₹44.95 ↓ ₹20.85 |
| 2020 | ₹22.90 | 52.6% | ↑ ₹32.80 ↓ ₹11.68 |
| 2019 | ₹15.00 | -33.7% | ↑ ₹24.30 ↓ ₹12.35 |
| 2018 | ₹22.60 | -29.4% | ↑ ₹35.80 ↓ ₹15.05 |
| 2017 | ₹32.00 | -34.7% | ↑ ₹73.00 ↓ ₹26.25 |
| 2016 | ₹49.00 | -17.8% | ↑ ₹79.45 ↓ ₹42.25 |
| 2015 | ₹59.55 | - | ↑ ₹91.25 ↓ ₹25.45 |
Analyzing the Impact of Investing in Concord Drugs
Concord Drugs Stock price in the year 2015 was ₹59.55. If you had invested ₹10,000 in Concord Drugs Stock in 2015, in 9 years, your investment would have reduced to ₹6,230 by the end of 2024. This represents a negative return of -37.7% from 2015 to 2024, with a compound annual growth rate (CAGR) of -5.2%.
Concord Drugs Stock Returns In Last 5 Years
- Its highest stock price in the last 5 years was: ₹61.50 and lowest was: ₹11.68
- Concord Drugs Stock price in 2019 was ₹15.00
- By 2024, its stock price rose to ₹37.10
- It gave a positive return of over 147.3% with a CAGR of 19.9% over the last 5 years
- If you had invested ₹10,000 in Concord Drugs in 2019 then in 5 years, your investment would have grown to ₹24,733.33 by 2024, which is 2.47 times of your initial investment.
Concord Drugs Returns vs Bank FD Returns
| Investment Type | Initial Amount | Final Value | Total Returns |
|---|---|---|---|
| Concord Drugs Shares | ₹10,000 | ₹6,230.05 | -37.7% |
| Bank FD (Simple Interest) | ₹10,000 | ₹15,400 | 54.0% |
| Bank FD (Compound Interest) | ₹10,000 | ₹16,894.78 | 68.9% |
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
